Plasma and serum are both liquid fractions of blood. Still, they are not the same material, and selecting the wrong one for your application can affect assay performance and data reliability. Plasma is collected before clotting occurs and retains fibrinogen and other coagulation proteins; serum is the fluid that remains after blood has clotted, which means those proteins are consumed or removed in the process. 

Understanding this biochemical distinction is the starting point for consistent selection of biological material across research and diagnostic workflows. Choosing correctly depends on your target analyte, your assay design, and whether coagulation proteins are relevant to your application.

What Is the Difference Between Plasma and Serum?

Plasma and serum both come from whole blood, but their protein compositions differ depending on when and how they are separated. The key distinction is coagulation: plasma is collected before clotting, and serum is collected after.

Human serum is commonly used in applications where anticoagulants would interfere with detection chemistry, including many ELISA formats and immunoassay validation workflows. Human plasma retains fibrinogen and other labile proteins generated during the clotting process. cascade, making it an appropriate matrix for coagulation studies and workflows that require a complete circulating protein profile. 

According to Physiology, Blood Plasma, published on StatPearls on NCBI Bookshelf, plasma accounts for approximately 55% of total blood volume and contains proteins, including albumin, globulins, and fibrinogen, at concentrations of approximately 6 to 8 g/dL.

How Serum and Plasma Are Collected

The collection process determines what proteins are present in the final product. Both matrices begin with whole blood, but handling diverges immediately depending on whether coagulation is permitted or inhibited.

Serum preparation requires adequate clotting time at room temperature before centrifugation. Insufficient clotting time can result in fibrin carry-over in the separated fraction, affecting downstream assay results. 

For plasma, the three most widely used anticoagulants each have distinct compatibility profiles: EDTA chelates calcium ions and is suited to protein and genomic work; heparin inhibits thrombin and factor Xa but may interfere with certain PCR-based detection systems; and sodium citrate is standard for coagulation studies where factor measurement is the primary objective. 

Available formats from Equitech-Bio, Inc. include donkey serum and human plasma variants with K2 EDTA, K3 EDTA, lithium heparin, sodium heparin, and sodium citrate anticoagulants, all confirmed on the live product catalog.

How to Choose Between Plasma and Serum for Research

The target analyte, assay design, and anticoagulant compatibility should drive matrix selection. Neither matrix is universally preferable; the correct choice depends on the specific research or diagnostic context.

Research published in Immunologic Research by Holden T. Maecker, Department of Microbiology and Immunology, Stanford University School of Medicine, concluded that “plasma is a more sensitive matrix for detecting changes in certain low-abundance cytokines” than serum in multiplex immunoassay formats, attributed in part to elevated non-specific background in serum resulting from platelet activation during clotting.

Beyond matrix type, the sourcing and processing parameters of the biological material directly affect assay performance. Key factors to verify when selecting serum or plasma for research or diagnostic use include:

• Species and donor origin
• Sterility status (sterile filtered or unfiltered)
• Anticoagulant type for plasma products
• Screening status (STD-negative for human-derived materials)
• Lot size and batch-to-batch consistency
• Storage format and cold chain documentation

Rat serum albumin and the broader Equitech Bio albumin range are available for matrix-matched assay controls and calibration workflows. All products are supplied for research use and in vitro diagnostic use only. 

Researchers should match the product matrix to the protocol requirements before ordering and request a reserve sample where lot verification is required before commitment. 

Contact Equitech-Bio at sales@equitech-bio.com or 800-259-0591 to discuss specifications and availability.

Conclusion

Plasma and serum differ primarily in their coagulation protein content, and that biochemical distinction determines which matrix is appropriate for a given application. 

Serum is suitable for assays where anticoagulants would interfere and where fibrinogen is not required; plasma is the appropriate choice when coagulation proteins are relevant or when a lower nonspecific background is needed for sensitive cytokine or biomarker detection. Lot consistency, documentation, and species specificity are equally important selection criteria regardless of matrix type. 

Equitech-Bio, Inc. supplies research-grade serum and plasma products across a wide range of species and anticoagulant formats, all produced under USDA oversight and ISO 13485:2016-certified quality management processes, for research and in vitro diagnostic use only.

FAQ